By SPC News Staff
The FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer.
The approval was based on data from the randomized, active-controlled, open-label, phase 3 CASPIAN trial (ClinicalTrials.gov Identifier: NCT03043872), in which durvalumab in combination with chemotherapy resulted in a statistically significant and clinically meaningful improvement in